The present invention relates to a high affinity, VNAR polypeptide cross reactive with
primate transferrin receptors (“TfR”). This TfR-specific VNAR polypeptide was obtained by screening semisynthetic VNAR
phage display libraries against recombinant human TfR-1. The VNAR polypeptides of the invention can be used alone or as a component in conjugates that target the
transferrin /
transferrin receptor transport system. The invention further includes use of this VNAR, its conjugates and other derivatives in diagnostic and therapeutic methods, e.g., to diagnose, treat and / or prevent a
pathological condition, disorder or
disease in which it is beneficial to deliver a
heterologous biomolecule across the
blood brain barrier or other membrane systems. This TfR-specific VNAR polypeptide can also be used to target other biological barriers such the intestines, the
placenta or aberrant cells overexpressing TfR-1, for therapeutic benefit in treatment of certain
cancer cells and tumors of various tissue types. Deimmunized VNAR scaffolds are also provided.